Norwalk, CT – March 9, 2023 – LifeSpan Vision Ventures today announced an investment in a promising startup which was previously spun out from Harvard’s Wyss Institute in Cambridge Massachusetts. The company, named Rejuvenate Bio, is a biotech company focused on reversing aging and eliminating age-related disease. Rejuvenate Bio utilizes gene therapy, proprietary targets, and tools to bring treatments to patients suffering from age-related conditions. The company is developing a pipeline of therapies with applications in cardiac and metabolic disease.
Andrew Worden, Founding Partner of LifeSpan Vision Ventures, stated: “Our investment in Rejuvenate Bio furthers our mission of supporting companies that develop therapeutics focusing on longevity and aging reversal. Rejuvenate’s strong team and legacy at the Wyss institute gives the company excellent prospects to succeed with its vision. We are excited to see this investment become a success as the team develops and launches therapeutics for canines and humans for hearts, joints, and more.”
About Rejuvenate Bio
Rejuvenate Bio is a spinout from the Wyss Institute at Harvard focused on reversing aging and eliminating age-related disease. Rejuvenate Bio utilizes gene therapy, proprietary targets, and tools to bring treatments to patients suffering from age-related conditions. The company is developing a pipeline of therapies with applications in cardiac and metabolic disease.
About LifeSpan Vision Ventures
Lifespan Vision Ventures invests in companies that develop diagnostics and therapeutics focusing on longevity and aging reversal.